The clinical application of
immune checkpoint inhibitors (ICIs) has significantly improved the
prognosis of
hepatocellular carcinoma (HCC)
patients . With the widespread applica-tion of ICIs in HCC, the management of immune-related adverse events (irAE) gained more and more
attention . However, the complicated
disease characteristics and various combination
therapies in HCC throw out challenges to irAE management. Therefore, the
editorial board of the '
Chinese expert
consensus on the management of immune-related adverse events of
hepatocellular carcinoma treated with
immune checkpoint inhibitors (2021 edition)' organizes multidisciplinary experts to discuss and formulate this
consensus . The
consensus focuses on issues related to HCC irAE manage-ment, and puts forward
suggestions , in order to improve standardized and
safety clinical medication, so as to maximize the benefits of
immunotherapy for
patients .